About This Event

CAMP4 Therapeutics Corporation (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, visits the Nasdaq MarketSite in Times Square.

In honor of the occasion, Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4, rings the Opening Bell.